P Jenner

Summary

Affiliation: King's College London
Country: UK

Publications

  1. ncbi Pharmacology of dopamine agonists in the treatment of Parkinson's disease
    Peter Jenner
    Neurodegenerative Diseases Research Centre, Guy s, King s, and St Thomas School of Biomedical Sciences, King s College, London, UK
    Neurology 58:S1-8. 2002
  2. ncbi Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline
    Peter Jenner
    Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King s College, London, UK
    Mov Disord 26:2316-23. 2011
  3. ncbi Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression
    P Jenner
    Neurodegenerative Disease Research Group, Institute of Pharmaceutical Sciences, School of Biomedical Sciences, King s College, London, UK
    J Neural Transm 118:1691-702. 2011
  4. ncbi Etiology and pathogenesis of Parkinson's disease
    Anthony H Schapira
    Department of Clinical Neurosciences, Institute of Neurology, University College, London, United Kingdom
    Mov Disord 26:1049-55. 2011
  5. ncbi Molecular mechanisms of L-DOPA-induced dyskinesia
    Peter Jenner
    King s College London, Guy s Campus, School of Health and Biomedical Sciences, London SE1 1UL, UK
    Nat Rev Neurosci 9:665-77. 2008
  6. ncbi From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease
    Peter Jenner
    Neurodegenerative Disease Research Centre, School of Health and Biomedical Sciences, King s College London, London, UK
    Parkinsonism Relat Disord 15:S18-23. 2009
  7. ncbi Adenosine, adenosine A 2A antagonists, and Parkinson's disease
    P Jenner
    Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King s College, London SE1 1UL, UK
    Parkinsonism Relat Disord 15:406-13. 2009
  8. ncbi Functional models of Parkinson's disease: a valuable tool in the development of novel therapies
    Peter Jenner
    Neurodegenerative Disease Research Centre, School of Health and Biomedical Sciences, King s College, London, United Kingdom
    Ann Neurol 64:S16-29. 2008
  9. ncbi Parkinson's disease, pesticides and mitochondrial dysfunction
    P Jenner
    King s College London, Manresa Road, London, UK SW3 6LX
    Trends Neurosci 24:245-7. 2001
  10. ncbi A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD
    Peter Jenner
    Neurodegenerative Diseases Research Centre, Guy s, King s and St Thomas School of Biomedical Sciences, King s College, London, UK
    Neurology 61:S32-8. 2003

Collaborators

Detail Information

Publications125 found, 100 shown here

  1. ncbi Pharmacology of dopamine agonists in the treatment of Parkinson's disease
    Peter Jenner
    Neurodegenerative Diseases Research Centre, Guy s, King s, and St Thomas School of Biomedical Sciences, King s College, London, UK
    Neurology 58:S1-8. 2002
    ....
  2. ncbi Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline
    Peter Jenner
    Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King s College, London, UK
    Mov Disord 26:2316-23. 2011
    ....
  3. ncbi Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression
    P Jenner
    Neurodegenerative Disease Research Group, Institute of Pharmaceutical Sciences, School of Biomedical Sciences, King s College, London, UK
    J Neural Transm 118:1691-702. 2011
    ..This review examines the rationale for CDD and explores the clinical benefit of using such a strategy for the treatment of patients with PD...
  4. ncbi Etiology and pathogenesis of Parkinson's disease
    Anthony H Schapira
    Department of Clinical Neurosciences, Institute of Neurology, University College, London, United Kingdom
    Mov Disord 26:1049-55. 2011
    ....
  5. ncbi Molecular mechanisms of L-DOPA-induced dyskinesia
    Peter Jenner
    King s College London, Guy s Campus, School of Health and Biomedical Sciences, London SE1 1UL, UK
    Nat Rev Neurosci 9:665-77. 2008
    ..The combination of nigral denervation and drug treatment establishes inappropriate signalling between the motor cortex and the striatum, leading to persistent dyskinesia...
  6. ncbi From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease
    Peter Jenner
    Neurodegenerative Disease Research Centre, School of Health and Biomedical Sciences, King s College London, London, UK
    Parkinsonism Relat Disord 15:S18-23. 2009
    ..Despite having been employed for almost 25 years, the MPTP-treated primate has many potential uses in the future that will further improve the treatment of PD...
  7. ncbi Adenosine, adenosine A 2A antagonists, and Parkinson's disease
    P Jenner
    Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King s College, London SE1 1UL, UK
    Parkinsonism Relat Disord 15:406-13. 2009
    ..Both epidemiologic evidence and the current preclinical data strongly support a role for A(2A) antagonists in protecting dopaminergic neurons and influencing the onset and progression of PD...
  8. ncbi Functional models of Parkinson's disease: a valuable tool in the development of novel therapies
    Peter Jenner
    Neurodegenerative Disease Research Centre, School of Health and Biomedical Sciences, King s College, London, United Kingdom
    Ann Neurol 64:S16-29. 2008
    ..They are an important reason the treatment of PD is so much better compared with treatments for related illnesses...
  9. ncbi Parkinson's disease, pesticides and mitochondrial dysfunction
    P Jenner
    King s College London, Manresa Road, London, UK SW3 6LX
    Trends Neurosci 24:245-7. 2001
    ..When vulnerable individuals become known, perhaps they should stay out of the garden...
  10. ncbi A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD
    Peter Jenner
    Neurodegenerative Diseases Research Centre, Guy s, King s and St Thomas School of Biomedical Sciences, King s College, London, UK
    Neurology 61:S32-8. 2003
    ....
  11. ncbi A novel dopamine agonist for the transdermal treatment of Parkinson's disease
    Peter Jenner
    Neurodegenerative Diseases Research Centre, Guy s, King s and St Thomas School of Biomedical Sciences, King s College, London, United Kingdom
    Neurology 65:S3-5. 2005
    ..The pharmacologic properties of rotigotine suggest that it has the characteristics necessary to form the basis of a transdermal treatment for the control of motor symptoms of PD...
  12. ncbi Oxidative stress in Parkinson's disease
    Peter Jenner
    Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King s College, London, United Kingdom
    Ann Neurol 53:S26-36; discussion S36-8. 2003
    ....
  13. ncbi The pathogenesis of cell death in Parkinson's disease
    Peter Jenner
    Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King s College, London, United Kingdom
    Neurology 66:S24-36. 2006
    ..This is an essential step to understanding pathogenesis and is critical to the development of comprehensive neuroprotective approaches to treatment...
  14. ncbi Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease
    Peter Jenner
    Neurodegenerative Diseases Research Centre, Guy's, King's and St Thomas' School of Biomedical Sciences, King's College, London, United Kingdom
    Neurology 63:S13-22. 2004
  15. ncbi Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult
    M Lee
    Wolfson Centre for Age-Related Diseases, Guy's, King's and St Thomas' School of Biomedical Sciences, King's College London, UK
    J Neurochem 76:998-1009. 2001
    ..The loss of viability induced by toxic insults was by apoptosic mechanism. The presence of abnormal alpha-synucleins in substantia nigra in PD may increase neuronal vulnerability to a range of toxic agents...
  16. ncbi Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset
    P Jenner
    Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy s, King s and St Thomas School of Biomedical Sciences, King s College, London, UK
    Exp Brain Res 133:178-88. 2000
    ..Behavioural and morphological evidence in the present study indicate a potential antiparkinsonian and neuroprotective role for modafinil, which may form a new pharmacological approach to the treatment of Parkinson's disease...
  17. ncbi Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or L-DOPA in MPTP-treated common marmosets
    K A Stockwell
    Neurodegenerative Disease Research Centre, School of Health and Biomedical Sciences, King s College, London, UK
    Exp Neurol 221:79-85. 2010
    ..In addition, while continuous delivery of rotigotine may prime for dyskinesia, it does not lead to its expression...
  18. ncbi Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction
    K A Stockwell
    Neurodegenerative Disease Research Group, School of Health and Biomedical Sciences, King s College, London, London, SE1 1UL, UK
    Exp Neurol 219:533-42. 2009
    ..However, continuous rotigotine administration did not prevent l-DOPA from inducing dyskinesia suggesting that l-DOPA may induce dyskinesia by mechanisms different from dopamine agonist drugs...
  19. ncbi Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
    E L Lane
    Neurodegenerative Disease Research Centre, GKT School of Biomedical Sciences, King s College, London, UK
    Exp Neurol 197:284-90. 2006
    ....
  20. ncbi Effect of overexpression of wild-type and mutant Cu/Zn-superoxide dismutases on oxidative damage and antioxidant defences: relevance to Down's syndrome and familial amyotrophic lateral sclerosis
    M Lee
    Wolfson Centre for Age-Related Diseases, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College London, UK
    J Neurochem 76:957-65. 2001
    ..They also show the potentially deleterious effects of SOD1 overexpression on cellular proliferation, which may be relevant to abnormal development in DS...
  21. ncbi Effect of proteasome inhibition on cellular oxidative damage, antioxidant defences and nitric oxide production
    M H Lee
    Wolfson Centre for Age-Related Diseases, Hodgkin Building, GKT School of Biomedical Sciences, King's College London, Guy's Campus, London Bridge, London SE1 1UL, UK
    J Neurochem 78:32-41. 2001
    ..The NO. production appeared to involve nNOS; iNOS or eNOS were not detectable in either cell type. Another proteasome inhibitor, epoxomicin, had similar effects...
  22. ncbi Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398
    E L Lane
    Neurodegenerative Disease Research Centre, School of Health and Biomedical Sciences, King s College, London, UK
    J Neural Transm 115:423-9. 2008
    ..An action in another area of the brain appears likely and may explain the subsequent failure of BTS 74 398 and related compounds to exert anti-parkinsonian actions in man...
  23. ncbi Effect of overexpression of wild-type and mutant Cu/Zn-superoxide dismutases on oxidative stress and cell death induced by hydrogen peroxide, 4-hydroxynonenal or serum deprivation: potentiation of injury by ALS-related mutant superoxide dismutases and pro
    M Lee
    Wolfson Centre for Age-Related Diseases, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College London, London, UK
    J Neurochem 78:209-20. 2001
    ..Overexpression of mutant SOD1s makes cells more predisposed to undergo apoptosis in response to several insults. Our cellular systems appear to mimic events in patients with ALS or transgenic mice overexpressing mutant SOD1...
  24. ncbi Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets
    B C Tel
    Neurodegenerative Disease Research Centre, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College, SE1 1UL, London, UK
    Neuroscience 115:1047-58. 2002
    ....
  25. ncbi The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats
    S A Treseder
    Neurodegenenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St Thomas' School of Biomedical Sciences, King's College, London, Guy's Campus, London, SE1 1UL, UK
    Eur J Neurosci 13:162-70. 2001
    ..NSD-1015, therefore, may not be an appropriate tool for the study of brain AADC activity and for assessing the neuromodulatory role of L-DOPA...
  26. ncbi The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets
    K Tayarani-Binazir
    Neurodegenerative Diseases Research Centre, School of Biomedical and Health Sciences, King s College, London, UK
    Exp Neurol 226:320-7. 2010
    ..These data suggest that pardoprunox may provide therapeutic benefit in mid to late stage PD by reducing dyskinesia while maintaining efficacy when used with concomitant l-dopa treatment...
  27. ncbi Proteasomal function is impaired in substantia nigra in Parkinson's disease
    K S McNaught
    Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St. Thomas' School of Biomedical Sciences, Hodgkin Building, King's College, Guy's Campus, SE1 1UL, London, UK
    Neurosci Lett 297:191-4. 2001
    ....
  28. ncbi Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets
    K A Stockwell
    Neurodegenerative Disease Research Group, School of Health and Biomedical Sciences, King s College London, London, UK
    Exp Neurol 211:172-9. 2008
    ..These results suggest that a once-daily controlled-release formulation may provide improvements over existing benefits with standard oral ropinirole in Parkinson's disease patients...
  29. ncbi Striatal leucine-rich repeat kinase 2 mRNA is increased in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned common marmosets (Callithrix jacchus) with L-3, 4-dihydroxyphenylalanine methyl ester-induced dyskinesia
    M J Hurley
    Neurodegenerative Diseases Research Group, Pharmaceutical Sciences Research Division, School of Biomedical and Health Sciences, King s College, London SE1 1UL, UK
    Eur J Neurosci 26:171-7. 2007
    ..The correlation between striatal Lrrk2 mRNA levels in MPTP-treated common marmoset striatum and L-DOPA-induced dyskinesia indicates that LRRK2 may have a role in the molecular alterations that cause L-DOPA-induced dyskinesia...
  30. ncbi Sonic hedgehog delivered by an adeno-associated virus protects dopaminergic neurones against 6-OHDA toxicity in the rat
    B Dass
    Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King's College, London, United Kingdom
    J Neural Transm 112:763-78. 2005
    ..However, the effects maybe dose limited due to uncoupling of hedgehog receptor signalling at higher levels of SHH expression...
  31. ncbi Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours
    E L Lane
    Neurodegenerative Disease Research Centre, GKT School of Biomedical Sciences, King's College, London SE1 1UL, UK
    Eur J Neurosci 21:179-86. 2005
    ..The lack of such changes following repeated BTS 74 398 treatment suggests that it may be an effective antiparkinsonian therapy that is unlikely to produce involuntary movements...
  32. ncbi Behavioural and immunohistochemical changes following supranigral administration of sonic hedgehog in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets
    B Dass
    Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, Kings College London, London SE1 1UL, UK
    Neuroscience 114:99-109. 2002
    ..SHH may improve nigro-striatal function by restoring tyrosine hydroxylase positivity. This is reflected by an improvement in basal disability and a reduction in the lesion-induced response to L-DOPA...
  33. ncbi The effect of chronic L-dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts
    S Blunt
    Parkinson s Disease Society Experimental Research Laboratories, King s College, Manresa Road, London, U K
    Neuroscience 40:453-64. 1991
    ..The continuation of L-DOPA therapy may not adversely affect fetal graft survival and growth in patients with Parkinson's disease...
  34. ncbi MPTP treatment of common marmosets impairs proteasomal enzyme activity and decreases expression of structural and regulatory elements of the 26S proteasome
    B-Y Zeng
    Neurodegenerative Disease Research Group, GKT School of Biomedical and Health Sciences, King's College, London, SE1 1UL, UK
    Eur J Neurosci 23:1766-74. 2006
    ..This suggests that altered proteasomal function in PD could be a consequence of other pathogenic processes occurring in SN as opposed to initiating cell death as previously suggested...
  35. ncbi 6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidase
    G Kunikowska
    Neurodegenerative Diseases Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St Thomas' School of Biomedical Sciences, Hodgkin Building, King's College, London SE1 1UL, UK
    Brain Res 922:51-64. 2001
    ..These findings may clarify the status of antioxidant enzymes, particularly Mn-SOD, in patients with Parkinson's disease and their relevance to disease pathogenesis...
  36. ncbi 6-Hydroxydopamine lesioning differentially affects alpha-synuclein mRNA expression in the nucleus accumbens, striatum and substantia nigra of adult rats
    B-Y Zeng
    Neurodegenerative Disease Research Centre, GKT School of Biomedical Sciences, King's College, London SE1 1UL, UK
    Neurosci Lett 322:33-6. 2002
    ..These data confirm that alpha-synuclein is localized in the nigro-striatal tract but that its gene expression is not regulated by dopamine...
  37. ncbi Chronic high dose L-dopa treatment does not alter the levels of dopamine D-1, D-2 or D-3 receptor in the striatum of normal monkeys: an autoradiographic study
    B Y Zeng
    Neurodegenerative Disease Research Centre, Guy's, King's and St Thomas' School of Biomedical Sciences, King's College, London, United Kingdom
    J Neural Transm 108:925-41. 2001
    ....
  38. ncbi Involvement of intrinsic cholinergic and GABAergic innervation in the effect of NMDA on striatal dopamine efflux and metabolism as assessed by microdialysis studies in freely moving rats
    K J Whitehead
    Neurodegenerative Diseases Research Centre, Hodgkin Building, Guy s, King s and St Thomas s School of Biomedical Sciences, King s College, Guy s Campus, London SE1 1UL, UK
    Eur J Neurosci 14:851-60. 2001
    ..Furthermore, NMDA-stimulated dopamine release also involves obligatory cholinergic facilitation and an inhibitory GABAergic component mediated through these respective receptors...
  39. ncbi L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease
    D R Cooper
    MRC Movement Disorders Research Group, University Department of Neurology, London, UK
    J Pharm Pharmacol 39:627-35. 1987
    ..Ester prodrugs of L-dopa may be as effective as L-dopa itself in producing motor activity but overall none of the compounds tested was markedly more potent or of longer duration than L-dopa itself...
  40. ncbi 6-hydroxydopamine increases the hydroxylation and nitration of phenylalanine in vivo: implication of peroxynitrite formation
    B Ferger
    Wolfson Centre for Age Related Diseases, Guy s, King s and St Thomas School of Biomedical Sciences, King s College London, London, UK
    J Neurochem 78:509-14. 2001
    ..We conclude that peroxynitrite formation is involved in 6-OHDA-induced neurochemical effects...
  41. ncbi Alterations in expression of dopamine receptors and neuropeptides in the striatum of GTP cyclohydrolase-deficient mice
    B-Y Zeng
    Neurodegenerative Disease Research Centre, GKT School of Biomedical Sciences, King's College, London SE1 1UL, UK
    Exp Neurol 190:515-24. 2004
    ..However, the pattern of changes observed is not that expected as a result of striatal dopamine deficiency and suggests that other effects of GTP cyclohydrolase I deficiency may be involved...
  42. ncbi Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets
    R K Pearce
    Neurodegenerative Diseases Research Centre, Biomedical Sciences Division, King s College London, and The National Hospital for Neurology, United Kingdom
    J Neural Transm 106:663-83. 1999
    ....
  43. ncbi Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets
    M J Hurley
    Neurodegenerative Diseases Research Group, Pharmaceutical Sciences Division, School of Health and Life Sciences, King s College, London, SE1 1UL, UK
    Eur J Neurosci 21:3240-50. 2005
    ..These results suggest that l-DOPA treatment of MPTP-lesioned marmosets can affect glutamatergic systems and indicate that altered NMDA receptor function may relate to dyskinesia...
  44. ncbi Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus)
    E C Maratos
    Neurodegenenerative Disease Research Centre, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College, London, United Kingdom
    Mov Disord 16:631-41. 2001
    ..These data suggest that in early Parkinson's disease, the use of ropinirole alone or in combination with a low-dose L-DOPA might delay the induction of dyskinesias while improving motor performance...
  45. ncbi 6-hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum
    B Ferger
    Wolfson Centre for Age-Related Diseases, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College London, London SE1 1UL, UK
    Neuroreport 12:1155-9. 2001
    ..Hydroxyl radical formation and DNA base alterations are early phenomena of 6-OHDA toxicity and provide clues to the processes that may be involved in the initiation of cell death in Parkinson's disease...
  46. ncbi Effect of overexpression of BCL-2 on cellular oxidative damage, nitric oxide production, antioxidant defenses, and the proteasome
    M Lee
    Wolfson Centre for Age-Related Diseases, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College London, London, UK
    Free Radic Biol Med 31:1550-9. 2001
    ....
  47. ncbi 3-Nitrotyrosine-dependent dopaminergic neurotoxicity following direct nigral administration of a peroxynitrite but not a nitric oxide donor
    M M Iravani
    Neurodegenerative Disease Research Centre, Guy's, King's and St Thomas' School of Biomedical Sciences, King's College, London SE1 1UL, UK
    Brain Res 1067:256-62. 2006
    ..The results suggest that increased NO formation is not inherently toxic to dopaminergic neurons, but when both oxidative and nitrative stress combine to cause peroxynitrite formation, neurotoxicity occurs...
  48. ncbi Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration
    M M Iravani
    Wolfson Centre for Age-Related Diseases, Neurodegenerative Disease Research Centre, Guy's, King's and St Thomas' School of Biomedical Sciences, Hodgkin Building, Guy's Campus, King's College, London SE1 1UL, UK
    Neuroscience 110:49-58. 2002
    ....
  49. ncbi L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations
    R K Pearce
    Neurodegenerative Diseases Research Centre, Hodgkin Building, Division of Pharmacology and Therapeutics, GKT School of Biomedical Sciences, King's College London, Guy's Campus, London Bridge, London SE1 1UL, UK
    Psychopharmacology (Berl) 156:402-9. 2001
    ..CONCLUSIONS: These results show for the first time that chronic oral L-dopa administration can provoke dyskinesias in primates independently of nigrostriatal damage, and that this effect is dose related...
  50. ncbi Modafinil prevents the MPTP-induced increase in GABAA receptor binding in the internal globus pallidus of MPTP-treated common marmosets
    B-Y Zeng
    Neurodegenerative Disease Research Centre, Guy's, King's and St Thomas' School of Biomedical Sciences, King's College, London SE1 1UL, UK
    Neurosci Lett 354:6-9. 2004
    ....
  51. ncbi What has been learnt from study of dopamine receptors in Parkinson's disease?
    M J Hurley
    Neurodegenerative Diseases Research Group, School of Biomedical and Health Sciences, King s College London, SE1 1UL, United Kingdom
    Pharmacol Ther 111:715-28. 2006
    ....
  52. ncbi L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates
    M Kuoppamaki
    Neurodegenerative Diseases Research Centre, King s College, London, U K
    J Neural Transm 114:1147-53. 2007
    ..Our results extend the relevance of the dyskinetic MPTP-treated primate in studying the genesis of involuntary movements occurring in L-dopa treated patients with PD...
  53. ncbi Striatal plasticity in Parkinson's disease and L-dopa induced dyskinesia
    M M Iravani
    Neurodegenerative Diseases Research Centre, Institute of Pharmaceutical Sciences, School of Biomedical Sciences, King s College, London, UK
    Parkinsonism Relat Disord 18:S123-5. 2012
    ..These lead to the onset of dyskinesia and underlie the priming process that characterise dyskinesia and its persistence...
  54. ncbi Commonly used L-amino acid decarboxylase inhibitors block monoamine oxidase activity in the rat
    S A Treseder
    Neurodegenerative Disease Research Centre, Guy s, King s and St Thomas School of Biomedical Sciences, King s College, London, United Kingdom
    J Neural Transm 110:229-38. 2003
    ..NSD-1015 should not be used to investigate the neuromodulatory role of L-DOPA as it potently inhibits rat striatal MAO...
  55. ncbi The effect of fenfluramine dosage regimen and reduced food intake on levels of 5-HT in rat brain
    S Rose
    Neurodegenerative Diseases Research Centre, King s College, London, United Kingdom
    J Neural Transm 104:1339-51. 1997
    ..These data suggest that escalating-doses of fenfluramine prevent the 5-HT-depleting effect of a sub-cute challenge without altering the anorexic action of the drug...
  56. ncbi Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease
    R K Pearce
    Neurodegenerative Diseases Research Centre, King s College, London, United Kingdom
    J Neural Transm 104:661-77. 1997
    ....
  57. ncbi Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors
    E L Lane
    GKT School of Biomedical Sciences, Hodgkin Building, Guy's Campus, London SE1 1UL, United Kingdom
    J Pharmacol Exp Ther 312:1124-31. 2005
    ..However, the mechanism of this interaction is complex, involving opposing effects of noradrenaline and 5-HT agonism and antagonism...
  58. ncbi Effects of desferrithiocin and its derivatives on peripheral iron and striatal dopamine and 5-hydroxytryptamine metabolism in the ferrocene-loaded rat
    D T Dexter
    Department of Neurodegenerative Disorders, Imperial College School of Medicine, London, UK
    Biochem Pharmacol 58:151-5. 1999
    ....
  59. ncbi Inhibition of neuronal nitric oxide synthase increases dopamine efflux from rat striatum
    M T Silva
    Neurodegenerative Diseases Research Centre, Guy's, King's and St Thomas' School of Biomedical Sciences, King's College, London, United Kingdom
    J Neural Transm 110:353-62. 2003
    ..Similarly, in conscious rats, L-NAME (1 mM) and 7-NINA (1 mM) increased DA efflux to 161% and 166% of basal efflux respectively. These data suggest that neuronally produced NO inhibits striatal DA efflux through an indirect mechanism...
  60. ncbi Halothane anesthesia affects NMDA-stimulated cholinergic and GABAergic modulation of striatal dopamine efflux and metabolism in the rat in vivo
    K J Whitehead
    Neurodegenerative Diseases Research Centre, Hodgkin Building, Guy s King s and St Thomas s School of Biomedical Sciences, King s College, Guy s Campus, London, United Kingdom
    Neurochem Res 29:835-42. 2004
    ....
  61. ncbi Proteasomal activity in brain differs between species and brain regions and changes with age
    B-Y Zeng
    Neurodegenerative Disease Research Centre, GKT School of Biomedical Sciences, King's College, London, UK
    Mech Ageing Dev 126:760-6. 2005
    ..This may explain the involvement of altered ubiquitin-proteasome system activity in Parkinson's disease and the relationship to ageing...
  62. ncbi Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys
    L Lyras
    Neurodegenerative Disease Research Centre, Guy's, King's and St Thomas' School of Biomedical Sciences, King's College, London, United Kingdom
    J Neural Transm 109:53-67. 2002
    ..Neither L-DOPA plus carbidopa nor L-DOPA plus carbidopa and entacapone led to obvious damage to the nigro-striatal pathway...
  63. ncbi Levodopa in the treatment of Parkinson's disease
    A H V Schapira
    Department of Clinical Neurosciences, Institute of Neurology, University College London, UK
    Eur J Neurol 16:982-9. 2009
    ..Maintaining good motor function and quality of life remain the primary goals of therapy and the principle that treatment must be tailored to the individual patient's needs is paramount...
  64. ncbi Perspectives on recent advances in the understanding and treatment of Parkinson's disease
    A H Schapira
    Department of Clinical Neurosciences, Institute of Neurology, University College London, London, UK
    Eur J Neurol 16:1090-9. 2009
    ..The value of existing and novel continuous drug delivery systems in PD is seen as providing simplified regimens, maintenance of motor control, reduction in motor complications and improved patient adherence to drug use...
  65. ncbi Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments
    P Jenner
    Neurodegenerative Process Research Center, Guy s King s and St Thomas School of Biomedical Sciences, King s College London, UK
    J Neurol 247:II43-50. 2000
    ....
  66. ncbi The actions of a D-1 agonist in MPTP treated primates show dependence on both D-1 and D-2 receptor function and tolerance on repeated administration
    L A Smith
    Neurodegenerative Disease Research Centre, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College, London, United Kingdom
    J Neural Transm 109:123-40. 2002
    ..36 mg/kg, subcutaneously) in a dose dependent manner. The dependence of the antiparkinsonian activity of A-77636 on intact D-2 receptor function, suggests a need for endogenous D-2 receptor tone to express D-1 mediated locomotor activity...
  67. ncbi Differential expression of cytochrome P450 enzymes in cultured and intact foetal rat ventral mesencephalon
    E A Gilbert
    Neurodegenerative Diseases Research Centre, Guy s King s and St Thomas School of Biomedical Sciences, King s College, London, UK
    J Neural Transm 110:1091-101. 2003
    ..Further investigation is now required to determine the functional implications as they may confer an altered level of susceptibility to neurotoxins between foetal and adult dopaminergic cells...
  68. ncbi Dopamine agonists in Parkinson's disease--focus on non-motor symptoms
    P Jenner
    Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College, London, UK
    Eur J Neurol 15:1. 2008
  69. ncbi Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on mitochondrial respiration
    K S McNaught
    Neurodegenerative Diseases Research Centre, King s College, London, U K
    Biochem Pharmacol 51:1503-11. 1996
    ..These findings suggest that isoquinoline derivatives may exert mitochondrial toxicity in vivo similar to that of MPTP/MPP+...
  70. ncbi Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia
    Mahmoud M Iravani
    Neurodegenerative Disease Research Centre, GKT School of Biomedical Sciences, King's College London, London SE1 1UL, UK
    Eur J Neurosci 22:1305-18. 2005
    ..This model allows the evaluation of pallidotomy-induced biochemical changes in dyskinetic primates...
  71. ncbi Novel pharmacological targets for the treatment of Parkinson's disease
    Anthony H V Schapira
    University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, Rowland Hill Street, London NW3 2PF, UK
    Nat Rev Drug Discov 5:845-54. 2006
    ....
  72. ncbi The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets
    Sarah Rose
    Neurodegenerative Disease Research Centre, School of Health and Biomedical Sciences, King's College, London SE1 1UL UK
    Eur J Pharmacol 546:82-7. 2006
    ..The data suggests that ST1535 will be an effective anti-parkinsonian agent in combination with L-DOPA and allow a reduction in l-DOPA usage in the treatment of Parkinson's disease...
  73. ncbi Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates
    Lance A Smith
    Neurodegenerative Diseases Research Group, School of Biomedical and Health Sciences, King's College, London, UK
    Clin Neuropharmacol 29:112-25. 2006
    ..Importantly, the results show that switching from levodopa to piribedil rapidly results in a sustained decrease in dyskinesia intensity...
  74. ncbi Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats
    Bai-Yun Zeng
    Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College, London, United Kingdom
    Ann Neurol 60:248-52. 2006
    ..Neuronal loss was also observed in the locus ceruleus, raphe nuclei, and dorsal motor nucleus of the vagus, verifying that proteasomal inhibition produces a relevant model of Parkinson's disease...
  75. ncbi Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss
    Joanna Iczkiewicz
    Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King s College, London SE1 1UL, UK
    Exp Neurol 207:95-106. 2007
    ..OPN appears to be an important regulator of nigral cell survival through its association with inflammatory events and its manipulation may provide a means of achieving neuroprotection in Parkinson's disease...
  76. ncbi Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets
    Regina Katzenschlager
    Reta Lila Weston Institute of Neurological Studies, University College London, UK
    Mov Disord 22:715-9. 2007
    ..The results of this first study of MIF in the marmoset MPTP model provide no encouragement for the reinvestigation of MIF in the clinical management of the motor signs of PD...
  77. ncbi Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates
    Sarah Rose
    aNeurodegenerative Disease Research Centre, School of Health and Biomedical Sciences, King s College London, UK
    Behav Pharmacol 18:155-60. 2007
    ..Plasma levels corresponding to the optimal dose range (0.01875-0.075 mg/kg) will guide a continuous administration regimen of rotigotine in a subsequent study using the same experimental model of Parkinson's disease...
  78. ncbi The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats
    Sarah Rose
    Neurodegenerative Disease Research Centre, School of Health and Biomedical Sciences, Kings College, London SE1 1UL, UK
    Brain Res 1133:110-4. 2007
    ..ST1535 may be useful in the treatment of Parkinson's disease and effective in reducing the use of l-dopa...
  79. ncbi The etiopathogenesis of Parkinson disease and suggestions for future research. Part II
    Irene Litvan
    University of Louisville School of Medicine, Louisville, Kentucky 40202, USA
    J Neuropathol Exp Neurol 66:329-36. 2007
    ..Topics reviewed in Part II are genetics, animal models, and oxidative stress...
  80. ncbi Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets
    Michael J Jackson
    Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King s College, London SE1 1UL, UK
    Exp Neurol 204:162-70. 2007
    ..In contrast, dopamine agonists may prime for dyskinesia, but do not lead to its full expression...
  81. ncbi The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates
    Mohammed Zubair
    Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King s College, London, SE1 1UL, UK
    Exp Neurol 208:177-84. 2007
    ..The results show that combined treatment with l-dopa and entacapone has a marked effect on dyskinesia induction even when therapy has been introduced with a dopamine agonist...
  82. ncbi Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease
    Joanna Iczkiewicz
    Neurodegenerative Diseases Research Centre, Guy s, King s and St Thomas School of Biomedical Sciences, King s College, London, UK
    Brain Res 1118:239-50. 2006
    ..The presence of OPN in the normal human and non-human primate SN coupled to its decreased expression following nigral cell degeneration suggests that it may play an important role in dopaminergic neurone survival...
  83. ncbi In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability
    Mahmoud M Iravani
    Neurodegenerative Disease Research Group, School of Health and Biomedical Sciences, King s College, London, United Kingdom
    J Pharmacol Exp Ther 319:1225-34. 2006
    ..These data suggest that selective 5-HT(1a) agonists do not provide an effective means of suppressing levodopa-induced dyskinesia, except with worsening of parkinsonism...
  84. ncbi Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems
    Nicholas Macinnes
    Wolfson Centre for Age Related Disease, King s College London, London, UK
    J Neural Transm 115:869-78. 2008
    ..These findings suggest that proteasomal abnormalities are present within cortical Lewy body disease and the experimental inhibition of proteasomal function mirrors the neuropathological changes seen within the disorder...
  85. ncbi Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response
    Mahmoud M Iravani
    Neurodegenerative Disease Research Centre, School of Health and Biomedical Sciences, King s College, London SE1 1UL, UK
    Exp Neurol 212:522-31. 2008
    ..Continuous infusion of pramipexole protected dopaminergic neurones against inflammation induced degeneration but without modification of the inflammatory response...
  86. ncbi Age-associated changes in protein oxidation and proteasome activities in rat brain: modulation by antioxidants
    Manal M Abd El Mohsen
    Molecular Nutrition Group, School of Food Biosciences, University of Reading, P O Box 226, Whiteknights, Reading RG6 6AP, UK
    Biochem Biophys Res Commun 336:386-91. 2005
    ..However, both melatonin and coenzyme Q10 treatments inhibited beta-glutamyl peptide hydrolase activity. This suggests that these molecules can alter proteasome function independently of their antioxidant actions...
  87. ncbi Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults
    Dong Hoon Hyun
    Neurodegenerative Disease Research Centre, GKT School of Biomedical Sciences, King s College, London, United Kingdom
    J Neurosci Res 82:232-44. 2005
    ..The viability loss induced by all the insults showed apoptotic features. The presence of parkin mutations in substantia nigra in Parkinson's disease may increase neuronal vulnerability to a range of toxic insults...
  88. ncbi Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure
    Lance A Smith
    Division of Pharmacology and Therapeutics, Guy's, King's, and St Thomas' School of Biomedical Sciences, King's College, London, United Kingdom
    Mov Disord 18:487-95. 2003
    ..Importantly, increasing pulsatile exposure of brain to L-dopa by preventing its peripheral breakdown also increases dyskinesia induction...
  89. ncbi Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease
    Grazyna Kunikowska
    Neurodegenerative Diseases Research Centre, Guy's, King's and St Thomas' School of Biomedical Sciences, King's College, London, UK
    Brain Res 968:206-18. 2003
    ....
  90. ncbi The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease
    Peter Jenner
    Neurodegenerative Disease Research Centre, Hodgkin Building, GKT School of Biomedical Sciences, King s College, SE1 1UL, London, UK
    Parkinsonism Relat Disord 9:131-7. 2003
    ....
  91. ncbi Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus)
    Eleni C Maratos
    Neurodegenenerative Disease Research Centre, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College London, London SE1 1UL, United Kingdom
    Exp Neurol 179:90-102. 2003
    ....
  92. ncbi Altered proteasomal function in sporadic Parkinson's disease
    Kevin St P McNaught
    Neurodegenerative Disease Research Centre, GKT School of Biomedical Sciences, King's College, London Bridge, London SE1 1UL, UK
    Exp Neurol 179:38-46. 2003
    ..These findings suggest that failure of the ubiquitin-proteasome system to adequately clear unwanted proteins may underlie vulnerability and degeneration of the SNc in both sporadic and familial PD...
  93. ncbi Aggresome-related biogenesis of Lewy bodies
    Kevin St P McNaught
    Department of Neurology, Mount Sinai School of Medicine, Annenberg 14 73, One Gustave L Levy Place, New York, NY 10029, USA
    Eur J Neurosci 16:2136-48. 2002
    ..This phenomenon is consistent with growing evidence that altered protein handling underlies the etiopathogenesis of PD and related disorders...
  94. ncbi Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa
    Mikko Kuoppamaki
    Neurodegenerative Diseases Research Centre, King s College, London, United Kingdom
    Mov Disord 17:1312-7. 2002
    ..Therefore, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated primates can provide a model in which the pathophysiology of treatment complications can be investigated...
  95. ncbi Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates
    Matthew J Hansard
    Neurodegenerative Disease Research Centre, Guy's, King's, and St. Thomas' School of Biomedical Sciences, King's College, London, United Kingdom
    J Pharmacol Exp Ther 303:952-8. 2002
    ..In contrast, there seems to be no role for NE or 5-HT reuptake inhibitors, and they may impair antiparkinsonian activity mediated through dopaminergic mechanisms...
  96. ncbi Proteasomal dysfunction induced by 4-hydroxy-2,3-trans-nonenal, an end-product of lipid peroxidation: a mechanism contributing to neurodegeneration?
    Dong Hoon Hyun
    Wolfson Centre for Age Related Diseases, GKT School of Biomedical Sciences, King s College, London, UK
    J Neurochem 83:360-70. 2002
    ..We propose that the proteasomal system is a significant target of HNE neurotoxicity in a wide range of neurodegenerative diseases, especially if abnormal proteins are being expressed...
  97. ncbi Effects of short- and long-term (--)-deprenyl administration on mRNA for copper, zinc- and manganese-superoxide dismutase and glutathione peroxidase in rat brain
    Grazyna Kunikowska
    Neurodegenerative Diseases Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St. Thomas School of Biomedical Sciences, Hodgkin Building, Guy's Campus, London SE1 1UL, UK
    Brain Res 953:1-11. 2002
    ..We conclude that (-)-deprenyl administration can induce mRNA expression for both forms of SOD, but the effects are variable and not sustained over 20 months...
  98. ncbi Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation
    Lance A Smith
    Neurodegenerative Diseases Research Centre, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College, London, United Kingdom
    Mov Disord 17:887-901. 2002
    ..L-dopa, but not Piribedil, reversed the decrease in preproenkephalin B mRNA produced by MPTP treatment...
  99. ncbi The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets
    Ronald K B Pearce
    Division of Pharmacology and Therapeutics, Guy's, King's and St. Thomas' School of Biomedical Sciences, London, United Kingdom
    Mov Disord 17:877-86. 2002
    ..These findings suggest that monoamine reuptake blockade may be of value in the treatment of Parkinson's disease, both early in the disease course and when L-dopa-induced dyskinesias complicate treatment...
  100. ncbi Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates
    Matthew J Hansard
    Neurodegenerative Disease Research Centre, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College, London SE1 1UL, UK
    Eur J Pharmacol 451:157-60. 2002
    ..Therefore, inhibition of dopamine reuptake does not evoke established dyskinesia in MPTP-treated primates...
  101. ncbi Proteasome inhibition causes nigral degeneration with inclusion bodies in rats
    Kevin St P McNaught
    Department of Neurology, Mount Sinai School of Medicine, Annenberg 14 73, One Gustave L Levy Place, New York, NY 10029, USA
    Neuroreport 13:1437-41. 2002
    ..These findings support the notion that failure of the ubiquitin-proteasome system to degrade and clear unwanted proteins is an important etiopathogenic factor in Parkinson's disease...